This content was funded by UCB Biopharma SRL
This infographic provides a summary of the MOGAD Masterclass 2024, an educational event initiated and funded by UCB Biopharma SRL to help raise awareness of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and to enable diagnosis.
MOGAD is a rare demyelinating disease of the central nervous system, with heterogeneous clinical manifestations, including acute disseminated encephalomyelitis, optic neuritis and transverse myelitis.1 With delegates from 16 countries attending this educational event, the MOGAD Masterclass 2024 was a forum where current and future management of the disease was discussed by a world-renowned panel of experts.
Other topics covered include:
- Challenges in diagnosis, despite the availability of MOGAD diagnostic consensus criteria;
- Latest expert insights into clinical and biological considerations around MOGAD; and
- Recent developments in imaging.
Read the full infographic for further details and key learnings from the event.
Reference
- Banwell B et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-82.
